Feed aggregator

The Bill Gates-Epstein Bombshell - and What Most People Get Wrong

Slashdot.org - Sat, 01/31/2026 - 10:34
The Daily Beast: "Salacious claims from Jeffrey Epstein that Bill Gates contracted an STD following 'sex with Russian girls,' and colluded with the disgraced financier on a plot to secretly slip his wife antibiotics, were revealed in the latest Epstein files release." The New York Times. (Alternate URL) "A representative of the Gates Foundation said, 'These claims — from a proven, disgruntled liar — are absolutely absurd and completely false. The only thing these documents demonstrate is Epstein's frustration that he did not have an ongoing relationship with Gates and the lengths he would go to entrap and defame.'" And Yahoo News points out the error of social media posts about the news: None paid attention to who actually wrote the email. The email was from Epstein — to Epstein... Both the "From" and "To" fields list Epstein's personal Gmail address. The message appears to be a draft, written during a period when Epstein's relationship with Gates had deteriorated. In it, Epstein alleges that Gates asked him to delete messages related to an STD. But the document does not show Gates making that request, nor does it provide independent confirmation that any of the claims are true. It reads like Epstein venting. It is not Gates confessing. "In a 2021 interview with CNN's Anderson Cooper, Gates called his relationship with the disgraced financier 'a huge mistake'," notes the New York Times. "He also sought to downplay his interactions with Epstein, saying he had several dinners with Epstein, with the hope of getting him to generate donations to the Gates Foundation."

Read more of this story at Slashdot.

Microdosing For Depression Appears To Work About As Well As Drinking Coffee

Slashdot.org - Sat, 01/31/2026 - 08:00
An anonymous reader quotes a report from Wired: About a decade ago, many media outlets -- including WIRED -- zeroed in on a weird trend at the intersection of mental health, drug science, and Silicon Valley biohacking: microdosing, or the practice of taking a small amount of a psychedelic drug seeking not full-blown hallucinatory revels but gentler, more stable effects. Typically using psilocybin mushrooms or LSD, the archetypal microdoser sought less melting walls and open-eye kaleidoscopic visuals than boosts in mood and energy, like a gentle spring breeze blowing through the mind. Anecdotal reports pitched microdosing as a kind of psychedelic Swiss Army knife, providing everything from increased focus to a spiked libido and (perhaps most promisingly) lowered reported levels of depression. It was a miracle for many. Others remained wary. Could 5 percent of a dose of acid really do all that? A new, wide-ranging study by an Australian biopharma company suggests that microdosing's benefits may indeed be drastically overstated -- at least when it comes to addressing symptoms of clinical depression. A Phase 2B trial of 89 adult patients conducted by Melbourne-based MindBio Therapeutics, investigating the effects of microdosing LSD in the treatment of major depressive disorder, found that the psychedelic was actually outperformed by a placebo. Across an eight-week period, symptoms were gauged using the Montgomery-Asberg Depression Rating Scale (MADRS), a widely recognized tool for the clinical evaluation of depression. The study has not yet been published. But MindBio's CEO Justin Hanka recently released the top-line results on his LinkedIn, eager to show that his company was "in front of the curve in microdosing research." He called it "the most vigorous placebo controlled trial ever performed in microdosing." It found that patients dosed with a small amount of LSD (ranging from 4 to 20g, or micrograms, well below the threshold of a mind-blowing hallucinogenic dose) showed observable upticks in feelings of well-being, but worse MADRS scores, compared to patients given a placebo in the form of a caffeine pill. (Because patients in psychedelic trials typically expect some kind of mind-altering effect, studies are often blinded using so-called "active placebos," like caffeine or methylphenidate, which have their own observable psychoactive properties.) This means, essentially, that a medium-strength cup of coffee may prove more beneficial in treating major depressive disorder than a tiny dose of acid. Good news for habitual caffeine users, perhaps, but less so for researchers (and biopharma startups) counting on the efficacy of psychedelic microdosing. "It's probably a nail in the coffin of using microdosing to treat clinical depression," Hanka says. "It probably improves the way depressed people feel -- just not enough to be clinically significant or statistically meaningful."

Read more of this story at Slashdot.

Author of Systemd Quits Microsoft To Prove Linux Can Be Trusted

Linux.Slashdot.org - Sat, 01/31/2026 - 05:00
Lennart Poettering has left Microsoft to co-found Amutable, a new Berlin-based company aiming to bring cryptographically verifiable integrity and deterministic trust guarantees to Linux systems. He said in a post on Mastodon that his "role in upstream maintenance for the Linux kernel will continue as it always has." Poettering will also continue to remain deeply involved in the systemd ecosystem. The Register reports: Linux celeb Lennart Poettering has left Microsoft and co-founded a new company, Amutable, with Chris Kuhl and Christian Brauner. Poettering is best known for systemd. After a lengthy stint at Red Hat, he joined Microsoft in 2022. Kuhl was a Microsoft employee until last year, and Brauner, who also joined Microsoft in 2022, left this month. [...] It is unclear why Poettering decided to leave Microsoft. We asked the company to comment but have not received a response. Other than the announcement of systemd 259 in December, Poettering's blog has been silent on the matter, aside from the announcement of Amutable this week. In its first post, the Amutable team wrote: "Over the coming months, we'll be pouring foundations for verification and building robust capabilities on top." It will be interesting to see what form this takes. In addition to Poettering, the lead developer of systemd, Amutable's team includes contributors and maintainers for projects such as Linux, Kubernetes, and containerd. Its members are also very familiar with the likes of Debian, Fedora, SUSE, and Ubuntu.

Read more of this story at Slashdot.

Categories: Linux

Author of Systemd Quits Microsoft To Prove Linux Can Be Trusted

Slashdot.org - Sat, 01/31/2026 - 05:00
Lennart Poettering has left Microsoft to co-found Amutable, a new Berlin-based company aiming to bring cryptographically verifiable integrity and deterministic trust guarantees to Linux systems. He said in a post on Mastodon that his "role in upstream maintenance for the Linux kernel will continue as it always has." Poettering will also continue to remain deeply involved in the systemd ecosystem. The Register reports: Linux celeb Lennart Poettering has left Microsoft and co-founded a new company, Amutable, with Chris Kuhl and Christian Brauner. Poettering is best known for systemd. After a lengthy stint at Red Hat, he joined Microsoft in 2022. Kuhl was a Microsoft employee until last year, and Brauner, who also joined Microsoft in 2022, left this month. [...] It is unclear why Poettering decided to leave Microsoft. We asked the company to comment but have not received a response. Other than the announcement of systemd 259 in December, Poettering's blog has been silent on the matter, aside from the announcement of Amutable this week. In its first post, the Amutable team wrote: "Over the coming months, we'll be pouring foundations for verification and building robust capabilities on top." It will be interesting to see what form this takes. In addition to Poettering, the lead developer of systemd, Amutable's team includes contributors and maintainers for projects such as Linux, Kubernetes, and containerd. Its members are also very familiar with the likes of Debian, Fedora, SUSE, and Ubuntu.

Read more of this story at Slashdot.

Syndicate content
Comment